{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:03:40Z","timestamp":1793246620277,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,6,6]],"date-time":"2016-06-06T00:00:00Z","timestamp":1465171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,6,6]],"date-time":"2016-06-06T00:00:00Z","timestamp":1465171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Contemporary guidelines suggest anticoagulant treatment decisions in atrial fibrillation (AF) patients to be based on risk stratification for stroke. However, guidelines do not agree on the threshold for treatment initiation. We explored the variation in thromboembolic event rates in a non-anticoagulated AF population, according to different guideline threshold and methodological approaches. AF patients between 1998 and 2014 free from anticoagulant treatment were identified. Event rates for ischemic stroke and ischemic stroke\/systemic embolism were explored. The overall ischemic stroke rate was 3.20 per 100 person-years (\u2018formal rate assessment\u2019). For patients with a CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc score of 1 the ischemic stroke rate was 0.97 when using a \u2018formal rate assessment\u2019, 0.62 when using a \u2018conditioning on the future\u2019 approach and 0.93 when using a \u2018censoring approach\u2019. Rates for thromboembolism for the \u2018European treatment threshold\u2019 (CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc score of 1, males only) ranged 1.17 to 1.53. Rates for the \u2018U.S. treatment threshold\u2019 (CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc of 2) ranged from 1.95 to 2.33. Thromboembolic event rates differed markedly in non-anticoagulated AF patients according to the conflicting European and U.S. guideline treatment thresholds. Second, the choice of methodological approach has implications, thus we recommend using the censoring approach for event rate estimation among AF patients not on treatment.<\/jats:p>","DOI":"10.1038\/srep27410","type":"journal-article","created":{"date-parts":[[2016,6,6]],"date-time":"2016-06-06T09:36:14Z","timestamp":1465205774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study"],"prefix":"10.1038","volume":"6","author":[{"given":"Peter Br\u00f8nnum","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben Bjerregaard","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flemming","family":"Skj\u00f8th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thure Filskov","family":"Overvad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,6]]},"reference":[{"key":"BFsrep27410_CR1","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/archinte.1995.00430050045005","volume":"155","author":"WM Feinberg","year":"1995","unstructured":"Feinberg, W. M., Blackshear, J. L., Laupacis, A., Kronmal, R. & Hart, R. G. Prevalence, age distribution and gender of patients with atrial fibrillation. Analysis and implications. Arch. Intern. Med. 155, 469\u2013473 (1995).","journal-title":"Arch. Intern. Med."},{"key":"BFsrep27410_CR2","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1093\/eurheartj\/eht280","volume":"34","author":"BP Krijthe","year":"2013","unstructured":"Krijthe, B. P. et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur. Heart J. 34, 2746\u20132751 (2013).","journal-title":"Eur. Heart J."},{"key":"BFsrep27410_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","volume":"129","author":"SS Chugh","year":"2014","unstructured":"Chugh, S. S. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 129, 837\u2013847 (2014).","journal-title":"Circulation"},{"key":"BFsrep27410_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/europace\/eun048","volume":"10","author":"A Ringborg","year":"2008","unstructured":"Ringborg, A. et al. Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace 10, 403\u2013411 (2008).","journal-title":"Europace"},{"key":"BFsrep27410_CR5","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1161\/01.STR.0000166053.83476.4a","volume":"36","author":"C Marini","year":"2005","unstructured":"Marini, C. et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 36, 1115\u20131119 (2005).","journal-title":"Stroke."},{"key":"BFsrep27410_CR6","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1161\/01.CIR.0000072767.89944.6E","volume":"107","author":"TJ Wang","year":"2003","unstructured":"Wang, T. J. et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham heart study. Circulation 107, 2920\u20132925 (2003).","journal-title":"Circulation"},{"key":"BFsrep27410_CR7","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.jacc.2006.10.062","volume":"49","author":"Y Miyasaka","year":"2007","unstructured":"Miyasaka, Y. et al. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J. Am. Coll. Cardiol. 49, 986\u2013992 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFsrep27410_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0002-9343(02)01236-6","volume":"113","author":"S Stewart","year":"2002","unstructured":"Stewart, S., Hart, C. L., Hole, D. J. & McMurray, J. J. V. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew\/Paisley study. Am. J. Med. 113, 359\u2013364 (2002).","journal-title":"Am. J. Med."},{"key":"BFsrep27410_CR9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"RG Hart","year":"2007","unstructured":"Hart, R. G., Pearce, L. A. & Aguilar, M. I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146, 857\u2013867 (2007).","journal-title":"Ann. Intern. Med."},{"key":"BFsrep27410_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GYH Lip","year":"2010","unstructured":"Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A. & Crijns, H. J. G. M. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137, 263\u2013272 (2010).","journal-title":"Chest"},{"key":"BFsrep27410_CR11","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","volume":"64","author":"CT January","year":"2014","unstructured":"January, C. T. et al. 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation. J. Am. Coll. Cardiol. 64, e1\u2013e76 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFsrep27410_CR12","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/europace\/eur416","volume":"14","author":"AJ Camm","year":"2012","unstructured":"Camm, A. J. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation - Developed with the special contribution of the European Heart Rhythm Association. Europace 14, 1385\u20131413 (2012).","journal-title":"Europace"},{"key":"BFsrep27410_CR13","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1160\/TH12-03-0175","volume":"107","author":"JB Olesen","year":"2012","unstructured":"Olesen, J. B., Torp-Pedersen, C., Hansen, M. L. & Lip, G. Y. H. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0\u20131: a nationwide cohort study. Thromb. Haemost. 107, 1172\u20131179 (2012).","journal-title":"Thromb. Haemost."},{"key":"BFsrep27410_CR14","doi-asserted-by":"publisher","first-page":"d124","DOI":"10.1136\/bmj.d124","volume":"342","author":"JB Olesen","year":"2011","unstructured":"Olesen, J. B. et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 342, d124 (2011).","journal-title":"BMJ"},{"key":"BFsrep27410_CR15","doi-asserted-by":"crossref","unstructured":"Quinn, G. & Singer, D. Reported stroke rates in patients with nonvalvular atrial fibrillation in North America are lower than those cited in ESC and AHA guidelines. In American Heart Association 2015 Scientific Sessions Abstract 319 (2015).","DOI":"10.1161\/circ.132.suppl_3.19336"},{"key":"BFsrep27410_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jacc.2014.10.052","volume":"65","author":"L Friberg","year":"2015","unstructured":"Friberg, L., Skeppholm, M. & Ter\u00e9nt, A. Benefit of Anticoagulation Unlikely in Patients With Atrial Fibrillation and a CHA2DS2-VASc Score of 1. J. Am. Coll. Cardiol. 65, 225\u2013232 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFsrep27410_CR17","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jacc.2015.05.044","volume":"66","author":"GYH Lip","year":"2015","unstructured":"Lip, G. Y. H., Skj\u00f8th, F., Rasmussen, L. H., Nielsen, P. B. & Larsen, T. B. Net Clinical Benefit for Oral Anticoagulation, Aspirin, or No Therapy in Nonvalvular Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex). J. Am. Coll. Cardiol. 66, 488\u2013490 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFsrep27410_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1403494810394717","volume":"39","author":"HW Kildemoes","year":"2011","unstructured":"Kildemoes, H. W., S\u00f8rensen, H. T. & Hallas, J. The Danish National Prescription Registry. Scand. J. Public Health 39, 38\u201341 (2011).","journal-title":"Scand. J. Public Health"},{"key":"BFsrep27410_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/1403494811401482","volume":"39","author":"E Lynge","year":"2011","unstructured":"Lynge, E., Sandegaard, J. L. & Rebolj, M. The Danish National Patient Register. Scand. J. Public Health 39, 30\u201333 (2011).","journal-title":"Scand. J. Public Health"},{"key":"BFsrep27410_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/1403494810387965","volume":"39","author":"CB Pedersen","year":"2011","unstructured":"Pedersen, C. B. The Danish Civil Registration System. Scand. J. Public Health 39, 22\u201325 (2011).","journal-title":"Scand. J. Public Health"},{"key":"BFsrep27410_CR21","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/jama.2015.10725","volume":"314","author":"L Melgaard","year":"2015","unstructured":"Melgaard, L. et al. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism and Death in Patients With Heart Failure With and Without Atrial Fibrillation. JAMA 314, 1030\u20131038 (2015).","journal-title":"JAMA"},{"key":"BFsrep27410_CR22","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1161\/CIRCULATIONAHA.115.015735","volume":"132","author":"PB Nielsen","year":"2015","unstructured":"Nielsen, P. B. et al. Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality and Bleeding: A Nationwide Cohort Study. Circulation 132, 517\u2013525 (2015).","journal-title":"Circulation"},{"key":"BFsrep27410_CR23","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1093\/ije\/dyr213","volume":"41","author":"PK Andersen","year":"2012","unstructured":"Andersen, P. K., Geskus, R. B., de Witte, T. & Putter, H. Competing risks in epidemiology: possibilities and pitfalls. Int. J. Epidemiol. 41, 861\u2013870 (2012).","journal-title":"Int. J. Epidemiol."},{"key":"BFsrep27410_CR24","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/sim.4385","volume":"31","author":"PK Andersen","year":"2012","unstructured":"Andersen, P. K. & Keiding, N. Interpretability and importance of functionals in competing risks and multistate models. Stat. Med. 31, 1074\u20131088 (2012).","journal-title":"Stat. Med."},{"key":"BFsrep27410_CR25","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1378\/chest.14-0533","volume":"146","author":"GYH Lip","year":"2014","unstructured":"Lip, G. Y. H. et al. The value of the European society of cardiology guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in atrial fibrillation stroke score: a nationwide co. Chest 146, 1337\u20131346 (2014).","journal-title":"Chest"},{"key":"BFsrep27410_CR26","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1160\/TH15-03-0210","volume":"113","author":"PB Nielsen","year":"2015","unstructured":"Nielsen, P. B. & Chao, T.-F. The risks of risk scores for stroke risk assessment in atrial fibrillation. Thromb. Haemost. 113, 1170\u20131173 (2015).","journal-title":"Thromb. Haemost."},{"key":"BFsrep27410_CR27","doi-asserted-by":"publisher","first-page":"927","DOI":"10.7326\/0003-4819-131-12-199912210-00004","volume":"131","author":"AS Go","year":"1999","unstructured":"Go, A. S. et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 131, 927\u2013934 (1999).","journal-title":"Ann Intern Med"},{"key":"BFsrep27410_CR28","doi-asserted-by":"crossref","first-page":"e000250","DOI":"10.1161\/JAHA.113.000250","volume":"2","author":"DE Singer","year":"2013","unstructured":"Singer, D. E. et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: The ATRIA study stroke risk score. J. Am. Heart Assoc. 2, e000250 (2013).","journal-title":"J. Am. Heart Assoc."},{"key":"BFsrep27410_CR29","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","volume":"285","author":"BF Gage","year":"2001","unstructured":"Gage, B. F. et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285, 2864\u20132870 (2001).","journal-title":"JAMA"},{"key":"BFsrep27410_CR30","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1160\/TH15-07-0565","volume":"114","author":"GYH Lip","year":"2015","unstructured":"Lip, G. Y. H., Skj\u00f8th, F., Nielsen, P. B. & Larsen, T. B. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. Thromb. Haemost. 114, 826\u2013834 (2015).","journal-title":"Thromb. Haemost."},{"key":"BFsrep27410_CR31","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1160\/TH15-05-0383","volume":"114","author":"AD Blann","year":"2015","unstructured":"Blann, A. D., Skj\u00f8th, F., Rasmussen, L. H., Larsen, T. B. & Lip, G. Y. H. Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. Thromb. Haemost. 114, 403\u2013409 (2015).","journal-title":"Thromb. Haemost."},{"key":"BFsrep27410_CR32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1161\/CIRCOUTCOMES.110.958108","volume":"4","author":"MH Eckman","year":"2011","unstructured":"Eckman, M. H., Singer, D. E., Rosand, J. & Greenberg, S. M. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 4, 14\u201321 (2011).","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"BFsrep27410_CR33","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff, C. T. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet 383, 955\u2013962 (2014).","journal-title":"Lancet"},{"key":"BFsrep27410_CR34","doi-asserted-by":"crossref","unstructured":"Lip, G. Y. H. et al. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. Europace euv269 (2015). 10.1093\/europace\/euv269","DOI":"10.1093\/europace\/euv269"},{"key":"BFsrep27410_CR35","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.mayocp.2016.03.007","volume":"91","author":"T-F Chao","year":"2016","unstructured":"Chao, T.-F. et al. Impact on Outcomes of Changing Treatment Guideline Recommendations for Stroke Prevention in Atrial Fibrillation: A Nationwide Cohort Study. Mayo Clin. Proc. 91, 567\u2013574 (2016).","journal-title":"Mayo Clin. Proc."},{"key":"BFsrep27410_CR36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3109\/14017431.2012.673728","volume":"46","author":"TA Rix","year":"2012","unstructured":"Rix, T. A. et al. Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry. Scand Cardiovasc J 46, 149\u2013153 (2012).","journal-title":"Scand Cardiovasc J"},{"key":"BFsrep27410_CR37","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000102143","volume":"28","author":"L-H Krarup","year":"2007","unstructured":"Krarup, L.-H., Boysen, G., Janjua, H., Prescott, E. & Truelsen, T. Validity of stroke diagnoses in a National Register of Patients. Neuroepidemiology 28, 150\u2013154 (2007).","journal-title":"Neuroepidemiology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep27410","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep27410.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep27410.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T15:35:46Z","timestamp":1672846546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep27410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,6]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,7,18]]}},"alternative-id":["BFsrep27410"],"URL":"https:\/\/doi.org\/10.1038\/srep27410","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,6]]},"assertion":[{"value":"14 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PBN: Speaker for Boehringer Ingelheim. GYHL: Guideline membership\/reviewing for various guidelines and position statements from ESC, EHRA, NICE etc. Steering Committees\/trials: Includes steering committees for various Phase II and III studies, Health Economics & Outcomes Research, etc. Investigator in various clinical trials in cardiovascular disease, including those on antithrombotic therapies in atrial fibrillation, acute coronary syndrome, lipids, etc. Consultant for Bayer\/Jensen J&J, Astellas, Merck, Sanofi, BMS\/Pfizer, Biotronik, Medtronic, Portola, Boehringer Ingelheim, Microlife and Daiichi-Sankyo. Speaker for Bayer, BMS\/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi-Sankyo. TBL: Investigator for Janssen Scientific Affairs, LLC and Boehringer Ingelheim and have been on the speaker bureaus for Bayer, BMS\/Pfizer, Roche Diagnostics, Boehringer Ingelheim and Takeda Pharma.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27410"}}